Industry Verticals »

All Categories

Insights »

About TMR »

Dyslipidemia Drugs Market

Dyslipidemia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the dyslipidemia drugs market for the historical period 2017–2018 and forecast period 2019–2027, increasing prevalence of population with cholesterol and triglyceride abnormalities is anticipated to drive the global dyslipidemia drugs market
  • According to the report, the global dyslipidemia drugs market was valued at US$ 11.8 Bn in 2018 and is projected to expand at a CAGR of 3.5% from 2019 to 2027

Global increasing prevalence of population with cholesterol and triglyceride abnormalities expected to propel the market: A Key Driver

  • Prevalence of cholesterol and triglyceride abnormalities is expected to increase exponentially across the world due to change in lifestyle and various factors such as obesity, lack of exercise, and poor dietary habits.
  • According to various government and private organizations operating in the cholesterol drugs industry, prevalence of dyslipidemia is rapidly increasing across the globe and is considered one of the serious cardiovascular conditions.
  • The Centers for Disease Control and Prevention (CDC) stated that around 95 million adults in the U.S. (55% of the total population) have total cholesterol levels higher than 200 mg/dL as of 2016. Furthermore, an estimated 29 million adult in U.S. have total cholesterol levels higher than 240 mg/dL.
  • Thus, the large population base suffering is expected to drive the global dyslipidemia drugs market during the forecast period.

Rising disease awareness through promotional activities

  • Several private and government organizations and key companies are actively engaged in increasing awareness about dyslipidemia through organizing various awareness campaigns or publishing guidelines for the same.
  • For instance, the National Lipid Association introduced “National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia”, aiming to provide guidelines for dyslipidemia patients related to cholesterol lowering drug therapy.
  • In October 2013, Pfizer, Inc. organized Dyslipidemia Awareness and Treatment program in collaboration with the International Atherosclerosis Society. The primary objective of this event was to improve treatment care for cardiovascular patients, particularly focused on dyslipidemia. These programs would increase awareness about dyslipidemia conditions among the patient population, leading to market growth.

Discontinuation of novel dyslipidemia drugs to Hamper Market

  • Discontinuation of under-development drug compounds such as dalcetrapib and Saroglitazar has hindered the growth of the market.
  • For example, in March 2017, Zydus Discovery DMCC suspended its study for safety and efficacy of Saroglitazar Magnesium in patients with dyslipidemias due to recruitment issues.
  • In May 2012, F. Hoffmann-La Roche Ltd. presented an update on phase III study of dalcetrapib (dal-OUTCOMES Phase III trial) to the independent Data and Safety Monitoring Board (DSMB). However, DSMB recommended discontinuation of the clinical trial due to the lack of clinical efficacy of the drug.
  • Thus, these discontinuations of dyslipidemia drugs hamper the growth of the market.

Global Dyslipidemia Drugs Market: Competitive Landscape

  • This report profiles major players in the global dyslipidemia drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Leading players operating in the global dyslipidemia drugs market are
  • Shionogi & Co., Ltd.
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Mylan N.V.
  • Amgen, Inc.
  • AstraZeneca plc
  • Abbott Laboratories.

Global Dyslipidemia Drugs Market: Key Developments

Key players in the global dyslipidemia drugs market are engaged in launch of new drugs for the treatment of dyslipidemia, and partnerships & collaborative agreements with other companies. These strategies of key players are likely to fuel the growth of the global dyslipidemia drugs market. A few expansion strategies adopted by players operating in the dyslipidemia drugs market are:

  • In November 2019, Novartis entered into an agreement to acquire The Medicines Company. He deal was valued at US$ 9.7 Bn. This acquisition is expected to expand the Novartis’s product portfolio. The acquisition adds the inclisiran drug to Novartis drug portfolio. Inclisiran is a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death.
  • In November 2019, Rentokil Initial plc acquired Florida Pest Control. It is a high quality service provider for residential and commercial customers. The purpose of this acquisition to acquire pest control businesses that build customer density and add to Rentokil Initial plc’s scale in key local markets.
  • In May 2019, Esperion announced that U.S. Food and Drug Administration (USFDA) has accepted the company’s New Drug Applications (NDAs) for bempedoic acid. bempedoic acid is a ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver.
  • In June 2017, Regeneron and Sanofi announced positive results from its Praluent (alirocumab) drug in hypercholesterolemia. The results shown the drug was superior to usual care in reducing non-high-density lipoprotein cholesterol (non-HDL-C) and also significantly reduced low-density lipoprotein cholesterol (LDL-C).
  • In August 2015, The U.S. Food and Drug Administration (USFDA) approved Amgen’s Repatha (evolocumab) drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease.

The report on the global dyslipidemia drugs market discussed individual strategies, followed by company profiles of providers of dyslipidemia drugs market. The ‘competitive landscape’ section has been included in the dyslipidemia drugs market report to provide readers with a dashboard view and a company market share analysis of key players operating in the global dyslipidemia drugs market.

Frequently Asked Questions

What is the total market worth of dyslipidemia drugs market?

Dyslipidemia drugs market to reach US$ 16.1 Bn by 2027

What is the anticipated CAGR of the dyslipidemia drugs market in the forecast period?

Dyslipidemia drugs market is projected to expand at a CAGR of 3.5% from 2019 to 2027

What are the key driving factors for the growth of the dyslipidemia drugs market?

Dyslipidemia drugs market is driven by increasing prevalence of population with cholesterol and triglyceride abnormalities

Which is the rising prominent segment in the dyslipidemia drugs market?

The retail pharmacies segment is likely to dominate the global dyslipidemia drugs market during the forecast period

Who are the key players in the dyslipidemia drugs market?

Key players in the global dyslipidemia drugs market include Shionogi & Co., Ltd., Pfizer, Inc., Merck & Co., Inc., Novartis AG, Bayer AG

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Dyslipidemia Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Dyslipidemia Drugs Market Introduction

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Dyslipidemia Drugs Market Analysis and Forecasts, 2017-2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Key Mergers & Acquisitions

        5.2. Pipeline Analysis

        5.3. Disease Prevalence & Incidence Rate globally with key countries

    6. Global Dyslipidemia Drugs Market Analysis and Forecasts, by Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast by Drug Class, 2017-2027

            6.3.1. Statins

            6.3.2. Bile Acid Resins

            6.3.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            6.3.4. Niacins

            6.3.5. Others

        6.4. Market Attractiveness by Drug Class

    7. Global Dyslipidemia Drugs Market Analysis and Forecasts, by Distribution Channel

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast by Distribution Channel, 2017-2027

            7.3.1. Hospital Pharmacies

            7.3.2. Retail Pharmacies

            7.3.3. Online Pharmacies

        7.4. Market Attractiveness by Distribution Channel

    8. Global Dyslipidemia Drugs Market Analysis and Forecasts, by Region

        8.1. Key Findings

        8.2. Market Value Forecast by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness by Country/Region

    9. North America Dyslipidemia Drugs Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast by Drug Class, 2017-2027

            9.2.1. Statins

            9.2.2. Bile Acid Resins

            9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            9.2.4. Niacins

            9.2.5. Others

        9.3. Market Value Forecast by Distribution Channel, 2017-2027

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Value Forecast by Country, 2017-2027

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Drug Class

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Dyslipidemia Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast by Drug Class, 2017-2027

            10.2.1. Statins

            10.2.2. Bile Acid Resins

            10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            10.2.4. Niacins

            10.2.5. Others

        10.3. Market Value Forecast by Distribution Channel, 2017-2027

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Online Pharmacies

        10.4. Market Value Forecast by Country/Sub-region, 2017-2027

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Drug Class

            10.5.2. By Distribution Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Dyslipidemia Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast by Drug Class, 2017-2027

            11.2.1. Statins

            11.2.2. Bile Acid Resins

            11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            11.2.4. Niacins

            11.2.5. Others

        11.3. Market Value Forecast by Distribution Channel, 2017-2027

            11.3.1. Hospital Pharmacies

            11.3.2. Retail Pharmacies

            11.3.3. Online Pharmacies

        11.4. Market Value Forecast by Country/Sub-region, 2017-2027

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Drug Class

            11.5.2. By Distribution Channel

            11.5.3. By Country/Sub-region

    12. Latin America Dyslipidemia Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast by Drug Class, 2017-2027

            12.2.1. Statins

            12.2.2. Bile Acid Resins

            12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            12.2.4. Niacins

            12.2.5. Others

        12.3. Market Value Forecast by Distribution Channel, 2017-2027

            12.3.1. Hospital Pharmacies

            12.3.2. Retail Pharmacies

            12.3.3. Online Pharmacies

        12.4. Market Value Forecast by Country/Sub-region, 2017-2027

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Drug Class

            12.5.2. By Distribution Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Dyslipidemia Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast by Drug Class, 2017-2027

            13.2.1. Statins

            13.2.2. Bile Acid Resins

            13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives

            13.2.4. Niacins

            13.2.5. Others

        13.3. Market Value Forecast by Distribution Channel, 2017-2027

            13.3.1. Hospital Pharmacies

            13.3.2. Retail Pharmacies

            13.3.3. Online Pharmacies

        13.4. Market Value Forecast by Country/Sub-region, 2017-2027

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Drug Class

            13.5.2. By Distribution Channel

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (by Tier and Size of companies)

        14.2. Market Share Analysis by Company (2018)

        14.3. Company Profiles

            14.3.1. Pfizer

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Growth Strategies

                14.3.1.3. SWOT Analysis

            14.3.2. Merck & Co., Inc.

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Growth Strategies

                14.3.2.3. SWOT Analysis

            14.3.3. Bayer AG

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Growth Strategies

                14.3.3.3. SWOT Analysis

            14.3.4. Mylan N.V.

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Growth Strategies

                14.3.4.3. SWOT Analysis

            14.3.5. Amgen

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Growth Strategies

                14.3.5.3. SWOT Analysis

            14.3.6. AstraZeneca plc

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Growth Strategies

                14.3.6.3. SWOT Analysis

            14.3.7. Abbott Laboratories

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Growth Strategies

                14.3.7.3. SWOT Analysis

            14.3.8. Bristol-Myers Squibb Company

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Growth Strategies

                14.3.8.3. SWOT Analysis

            14.3.9. Novartis AG

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Growth Strategies

                14.3.9.3. SWOT Analysis

            14.3.10. Shionogi & Co., Ltd.

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Growth Strategies

                14.3.10.3. SWOT Analysis

    List of Tables

    Table 01: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 02: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

    Table 03: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2027

    Table 04: North America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2027

    Table 05: North America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 06: North America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

    Table 07: Europe Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 08: Europe Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 09: Europe Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

    Table 10: Asia Pacific Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 11: Asia Pacific Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 12: Asia Pacific Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

    Table 13: Latin America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 14: Latin America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 15: Latin America Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

    Table 16: Middle East & Africa Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 17: Middle East & Africa Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

    Table 18: Middle East & Africa Dyslipidemia Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

    List of Figures

    Figure 01: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast, 2017-2027

    Figure 02: Global Dyslipidemia Drugs Market Value Share, by Drug Class, 2018

    Figure 03: Global Dyslipidemia Drugs Market Value Share, by Distribution Channel, 2018

    Figure 04: Global Dyslipidemia Drugs Market Value Share, by Region, 2018

    Figure 05: Global Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 06: Global Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027

    Figure 07: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Statins, 2017-2027

    Figure 08: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Bile Acid Resins, 2017-2027

    Figure 09: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Fibric Acid and Omega-3 Fatty Acid Derivatives, 2017-2027

    Figure 10: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Niacins, 2017-2027

    Figure 11: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017-2027

    Figure 12: Global Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 13: Global Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027

    Figure 14: Global Dyslipidemia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017-2027

    Figure 15:Figure 22: Global Dyslipidemia Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2017-2027

    Figure 16: Global Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2017-2027

    Figure 17: Global Dyslipidemia Drugs Market Value Share, by Region, 2018 and 2027

    Figure 18: Global Dyslipidemia Drugs Market Attractiveness, by Region, 2019-2027

    Figure 19: North America Dyslipidemia Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027

    Figure 20: North America Dyslipidemia Drugs Market Value Share (%) Analysis, by Country, 2018 & 2027

    Figure 21: North America Dyslipidemia Drugs Market Attractiveness Analysis, by Country, 2019?2027

    Figure 22: North America Dyslipidemia Drugs Market Value Share (%) Analysis, by Drug Class, 2018 & 2027

    Figure 23: North America Dyslipidemia Drugs Market Attractiveness, by Drug Class, 2019?2027

    Figure 24: North America Dyslipidemia Drugs Market Value Share (%) Analysis, by Distribution Channel, 2018 & 2027

    Figure 25: North America Dyslipidemia Drugs Market Attractiveness, by Distribution Channel, 2019?2027

    Figure 26: Europe Dyslipidemia Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027

    Figure 27: Europe Dyslipidemia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 28: Europe Dyslipidemia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019?2027

    Figure 29: Europe Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 30: Europe Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019?2027

    Figure 31: Europe Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 32: Europe Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019?2027

    Figure 33: Asia Pacific Dyslipidemia Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027

    Figure 34: Asia Pacific Dyslipidemia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 35: Asia Pacific Dyslipidemia Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027

    Figure 36: Asia Pacific Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 37: Asia Pacific Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027

    Figure 38: Asia Pacific Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 39: Asia Pacific Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027

    Figure 40: Latin America Dyslipidemia Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027

    Figure 41: Latin America Dyslipidemia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 42: Latin America Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027

    Figure 43: Latin America Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 44: Latin America Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027

    Figure 45: Latin America Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 46: Latin America Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027

    Figure 47: Middle East & Africa Dyslipidemia Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027

    Figure 48: Middle East & Africa Dyslipidemia Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 49: Middle East & Africa Multiple Sclerosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027

    Figure 50: Middle East & Africa Dyslipidemia Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

    Figure 51: Middle East & Africa Dyslipidemia Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027

    Figure 52: Middle East & Africa Dyslipidemia Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 53: Middle East & Africa Dyslipidemia Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027

    Figure 54: Global Dyslipidemia Drugs Market Share Analysis, by Company, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved

Dyslipidemia Drugs Market

Schedule a Call